Ligand News and Research

RSS

In silico screening of natural ACE2 inhibitors

Researchers identify potential ACE2 inhibitors through a virtual screening protocol.

14 Mar 2022

Further optimization of cysteine-reactive pyrazoline-based covalent inhibitors for the SARS-CoV-2 Mpro

Researchers discovered and optimized cysteine-reactive pyrazoline-based covalent inhibitors for several coronaviruses' Mpro, including SARS-CoV-2.

11 Mar 2022

Study explores differentially expressed immune genes for COVID-19 patient stratification

In a new study, researchers determined the transcriptional signatures associated with the severity of COVID-19.

7 Mar 2022

Severity-dependent immune mechanisms in the cerebrospinal fluid and plasma of COVID-19 patients

Researchers determined the immune mechanisms associated with severe neurological manifestations of COVID-19.

7 Mar 2022

Dual therapeutic potential of zapnometinib against COVID-19

Researchers assessed the impact of the drug zapnometinib on human immune response against coronavirus disease 2019.

2 Mar 2022

A ubiquitous protein may be key to the survival of neurons most impacted by glaucoma

A ubiquitous protein called sigma 1 receptor, which is known to protect cells from stress, appears key to the function and survival of the neurons most impacted by glaucoma, scientists report.

1 Mar 2022

Study explores the boosting of SARS-CoV-2 adenovirus vaccine-induced immunity by capsid decoration

Researchers demonstrated that decorating the capsid surface of adenovirus vaccine vectors with a newly discovered protein superglue, DogTag/DogCatcher generates potent SARS-CoV-2-specific humoral and cellular immunity.

24 Feb 2022

Study explores the impact of COVID-19 on pancreatic cells

New study findings showed that SARS-CoV-2 caused a productive yet restricted infection of pancreatic islet cells and an insignificant inflammatory response.

23 Feb 2022

hAELVi cell infection model mimics SARS-CoV-2 Omicron infection in lower respiratory tract of humans

In a recent study posted to the Research Square* preprint server, which is under consideration at Scientific Reports, a team of researchers developed a novel human Alveolar Epithelial Lentivirus immortalized (hAELVi) cell infection model to estimate the replication potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses in the lower respiratory tract of humans.

23 Feb 2022

TTUHSC expert wins NIH renewal grant to continue research on neurological disorders

According to the Global Burden of Disease study, neurological disorders are the leading cause of disability and the second leading cause of death after heart disease.

21 Feb 2022

Structure of protein that can pump toxic molecules out of bacterial cells revealed

MIT chemists have discovered the structure of a protein that can pump toxic molecules out of bacterial cells. Proteins similar to this one, which is found in E. coli, are believed to help bacteria become resistant to multiple antibiotics.

18 Feb 2022

Researchers find potential new strategy to treat metastatic form of intra-abdominal cancer

Researchers from the National Cancer Centre Singapore (NCCS) have found a potential new strategy to treat peritoneal carcinomatosis, a metastatic form of intra-abdominal cancer, where patients are presented with limited treatment options and poor overall survival.

15 Feb 2022

SARS-CoV-2 cytokine storm inhibited by curcumin nanoparticles

In a recent study published in the journal ACS Applied Bio Materials, researchers demonstrated the inhibitory potential of curcumin-encapsulated polysaccharide nanoparticles (CUR−PS-NPs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (CoV2-SP)-stimulated cytokine storm in lung and liver epithelial cells.

8 Feb 2022

Study uncovers a series of natural products that can inhibit the main protease of SARS-CoV-2

The fight against the COVID-19 pandemic is an international scientific challenge regarding the search for strategies to fight the viral infection and prevent its damaging consequences.

7 Feb 2022

Investigating taraxerol as a protease inhibitor against SARS-CoV-2

In a recent study posted to the Research Square preprint* server, a team of researchers investigated the toxicity and absorption, distribution, metabolism, and excretion (ADME) characteristics of a potent herbal drug, taraxerol, in the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The paper is under consideration for publication in the Structural Chemistry journal.

7 Feb 2022

Using interdisciplinary approach to beat cancer

European Cooperation in Science and Technology (COST) World Cancer Day aims at raising awareness of cancer and to encourage its prevention, detection, and treatment.

4 Feb 2022

Study describes the first three days of SARS-CoV-2 infection in an ALI model of proximal airway epithelium

Researchers evaluated the initial three days of SARS-CoV-2 infection via scRNAseq dataset in humanized in vitro model.

3 Feb 2022

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells – a "back up" approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.

2 Feb 2022

New nanoparticle SARS-CoV-2 vaccine shows stronger, broader, and more durable protection

The first generation of COVID-19 vaccines have been highly effective, but also have limitations: their efficacy can wane without a booster shot, and they may be less effective against some variants.